Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29907623.
- Also identified by DOI 10.1158/1078-0432.CCR-18-1475.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunosenescence might be expected to reduce the efficacy of checkpoint blockade, which depends on a functionally intact immune system. However, it seems that older patients with melanoma may respond better to anti-PD-1 treatment than younger patients, possibly due to their having fewer regulatory T cells relative to CD8<sup>+</sup> T cells within tumor deposits. <i>Clin Cancer Res; 24(21); 5193-4. ©2018 AACR</i> <i>See related article by Kugel et al., p. 5347</i>.
Medical subject headings
- Melanoma
- T-Lymphocytes, Regulatory